# Adebrelimab Injection (PD-L1) Combined With Short Course Radiotherapy and Chemotherapy for Neoadjuvant Therapy of Locally Advanced Rectal Cancer

> **NCT06765616** · PHASE2 · RECRUITING · sponsor: **Feng Tian** · enrollment: 31 (estimated)

## Conditions studied

- Rectal Cancer
- Advanced Stage Colorectal Cancer
- Radiotherapy

## Interventions

- **DRUG:** Adebrelimab Injection combined with radiotherapy and chemotherapy

## Key facts

- **NCT ID:** NCT06765616
- **Lead sponsor:** Feng Tian
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-01
- **Primary completion:** 2025-07-01
- **Final completion:** 2026-07-01
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2025-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06765616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06765616, "Adebrelimab Injection (PD-L1) Combined With Short Course Radiotherapy and Chemotherapy for Neoadjuvant Therapy of Locally Advanced Rectal Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06765616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*